Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Integral Diagnostics Ltd. ( (AU:IDX) ) has issued an update.
Integral Diagnostics Ltd. reported a significant financial turnaround for the year ended June 30, 2025, with revenues increasing by 33.5% to $627.2 million and a notable improvement in profitability metrics such as EBITDA and EBITA. The company’s strong performance is reflected in the declaration of a fully franked final dividend of 4.0 cents per share, indicating robust financial health and a positive outlook for stakeholders.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. operates in the healthcare industry, specializing in diagnostic imaging services. The company focuses on providing high-quality medical imaging services across Australia and New Zealand, leveraging advanced technology and a team of skilled professionals to deliver accurate and timely diagnostic results.
Average Trading Volume: 1,043,981
Technical Sentiment Signal: Buy
Current Market Cap: A$998.1M
Learn more about IDX stock on TipRanks’ Stock Analysis page.